Trials / Unknown
UnknownNCT05761652
An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 378 (estimated)
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
Based on the characteristics of symptoms, differences in physical and chemical examinations and tests, and characteristics of traditional Chinese medicine (TCM) disease differentiation and syndrome differentiation, the evaluation indicators for the clinical early warning model were screened, and the "three-level early warning mechanism for COVID-19 patients at high risks, with progression to severe cases and sequelae was constructed.
Detailed description
Adopt multi-level evidence base architecture, build "multi-source data analysis, feature extraction, multi-level evidence extraction, active The integrated Chinese and Western medicine big data platform integrates the original evidence processing into a multi-level evidence base, comprehensive analysis of The platform will generate a multi-level evidence base by processing the original evidence, analyze the evaluation indexes of New Coronary Pneumonia, select the features, build a deep neural network model, train and validate the model, and establish a high The model is trained and validated, and a three-level early warning model is established for people at high risk of new coronary pneumonia, those who turn serious, and those with sequelae.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observe and record | The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed. |
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-02-01
- Completion
- 2024-06-01
- First posted
- 2023-03-09
- Last updated
- 2023-03-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05761652. Inclusion in this directory is not an endorsement.